Roivant Sciences (ROIV) Capital Expenditures (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Capital Expenditures data on file, last reported at $6.9 million in Q4 2025.

• Quarterly Capital Expenditures rose 83.42% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 233.52% YoY) and the FY2026 annual result came in at $7.4 million, up 61.25% from the prior year.
• Capital Expenditures retreated to $6.9 million in Q4 2025, from $7.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.2 million in Q4 2021 to a low of $275000.0 in Q3 2023.
• A 5-year average of $4.3 million and a median of $3.1 million in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 94.6% — and 2025, when it soared 687.95%.
• Tracing ROIV's Capital Expenditures over 5 years: stood at $11.2 million in 2021, then declined by 0.94% to $11.1 million in 2022, then tumbled by 90.67% to $1.0 million in 2023, then surged by 266.7% to $3.8 million in 2024, then soared by 83.42% to $6.9 million in 2025.
• The last three Capital Expenditures figures came in at $6.9 million (Q4 2025), $7.8 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.